Fusion Pharmaceuticals Inc FUSN

NAS: FUSN | ISIN: CA36118A1003   20/05/2024
21,53 USD (+0,09%)
(+0,09%)   20/05/2024
Grafiek Fusion Pharmaceuticals Inc Grafiek Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc in het nieuws

9 mei 2024 · Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer · Persbericht

7 mei 2024 · Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates · Persbericht

25 april 2024 · Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order · Persbericht

9 april 2024 · Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 · Persbericht

27 maart 2024 · INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN · Persbericht

20 maart 2024 · Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates · Persbericht

19 maart 2024 · Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer · Persbericht

6 maart 2024 · Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

5 maart 2024 · Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting · Persbericht

26 februari 2024 · Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences · Persbericht

Profiel Fusion Pharmaceuticals Inc

Farmaceutica
Gezondheidstechnologie
Productie
Productie van biologische producten

Werknemers: 101

Aandelen Fusion Pharmaceuticals Inc

Beurswaarde: 1,83 miljard USD

Effecten: 85,06 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 0,43

Mijn selecties